BioInnovation Institute (BII) is adjusting the composition of its Board of Directors as part of a strategic strengthening of the institute’s international profile. The change follows BII’s ambition and recent announcements regarding the establishment of new funds focused on investments in the United Kingdom and Italy and is intended to support the organization’s continued expansion.
Danish biotech entrepreneur Hans Schambye is stepping down from the board in connection with his appointment as CEO of Boost Pharma. He is succeeded by American business executive Jim Glasheen, Chief Executive of Cambridge Enterprise, the innovation arm of the University of Cambridge.
Chair of the Board Marianne Philip emphasizes that the change is a natural consequence of BII’s development:
“Hans has played an absolutely central role in the success we have achieved since our establishment in 2017. With his extensive experience in translating research into commercial solutions and his strong network within the Danish biotech sector, he has been an invaluable part of the board’s work,” she says, and continues:
“As we expand our European activities, we have wanted to add further international competencies to the board, and we are therefore very pleased to welcome Jim Glasheen.”
Read full press release